Advertisement

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x100px
Person › Details

Jan Medina (InflaRx N.V. (Nasdaq Global Select Market: IFRX))

Medina, Jan (InflaRx 202402– Head of Investor Relations before Olink Proteomics)

 

Organisations Organisation InflaRx N.V. (Nasdaq Global Select Market: IFRX)
  Group InflaRx (Group)
  Former/major organisation Olink Bioscience AB (Olink Proteomics)
  Today Navinci Diagnostics AB
  Group Navinci Diagnostics AB
Products Product public relations / investor relations / marcom (services)
  Product 2 INF904 (InflaRx)
     

InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena.

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital markets will be invaluable as we continue to advance our clinical programs and strengthen our relationships with the investor community.”

Jan Medina commented: "It's a privilege to join InflaRx during this exciting time, with its strong execution and as the Company broadens its development efforts to meaningfully improve the treatment of chronic immune-inflammatory diseases. I am particularly excited about the promise of our new oral C5aR inhibitor INF904, which recently provided evidence of best-in-class potential. In addition, our late-stage asset vilobelimab is now in Phase III for pyoderma gangrenosum, an unmet medical need with no drug approved in the U.S. or Europe. I look forward to working with the dedicated team at InflaRx as we continue our next phase of pipeline value creation.”

Jan joins InflaRx from Olink Proteomics where he was Vice President, Investor Relations & Capital Markets. His previous IR experience includes roles at consultancy firms and at companies focused on oncology, immuno-oncology, hematology, specialty therapeutics and medical technology, ranging from early-stage ventures to global commercial entities. Jan’s sell-side experience includes roles within boutique and specialty research firms, as well as positions at several global investment banks. On the buy-side, Jan focused on healthcare and biotech. He holds a Bachelor of Science in Biomedical Engineering from Tulane University School of Engineering and is a CFA charterholder.


About InflaRx

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.


Contacts:

InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email:[email protected]

MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email:[email protected]
Europe: +49 89-210 2280
US: +1-339-832-0752


FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals and related treatment recommendations by medical/healthcare institutes and other third-party organizations, our ability to successfully commercialize and the receptiveness of Gohibic (vilobelimab) as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals or our other product candidates; our expectations regarding the size of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and clinical utility of Gohibic (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates, under an Emergency Use Authorization and in the future if approved for commercial use in the United States or elsewhere; our ability to successfully implement The InflaRx Commitment Program, the success of our future clinical trials for vilobelimab’s treatment of COVID-19 and other debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum, and any other product candidates, including INF904, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of our product candidates and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our Marketing Authorization Application submission for vilobelimab and our biologics license application submission for Gohibic (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for any indication; whether the U.S. Food and Drug Administration, the European Medicines Agency or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our expectations regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product Gohibic (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

   
Record changed: 2024-09-01

Advertisement

Picture biomindz Brand LSE Mainz Place to Biotech 650x200px


More documents for Jan Medina


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x300px




» top